Jan M. Griffin
Columbia University
Cardiac function curveTransthyretinInternal medicineCardiologyRetrospective cohort studyIntensive care medicineHemodynamicsEmergency medicineAdverse effectExtracorporeal membrane oxygenationCardiac amyloidosisHeart failureVentricular assist deviceCardiomyopathyHeart transplantationTafamidisDiseaseAmyloidosisImmunosuppressionImplantPopulationCoronavirus disease 2019 (COVID-19)In patientPost-hoc analysisMedicineEjection fractionGastroenterology
53Publications
4H-index
780Citations
Publications 44
Newest
#1Jan M. Griffin (Columbia University)H-Index: 4
#2Jessica E. Chasler (Johns Hopkins University)H-Index: 3
Last. Edward K. Kasper (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 7
view all 0 authors...
Abstract null null Background null Cardiac sarcoidosis (CS) is a major cause of morbidity and mortality in patients with systemic sarcoidosis. Steroid sparing agents are increasingly used, despite lack of randomized trials or published guidelines to direct treatment. null null null Methods null This retrospective study included 77 patients with CS treated with prednisone monotherapy (n=32) or a combination with mycophenolate mofetil (MMF) (n=45) between 2003 and 2018. Baseline characteristics an...
1 CitationsSource
#1Jan M. Griffin (Columbia University)H-Index: 4
#2Richard Cheng (University of Washington Medical Center)H-Index: 19
Over the last decade, treatment for heart failure with reduced ejection fraction (HFrEF) has advanced, with the incremental addition of novel evidence-based medical therapies. The landmark PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) study showed that the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan was superior to enalapril in reducing risk of death and HF hospitalisations.1 This has paved ...
Source
Introduction null Hereditary transthyretin-mediated (hATTR) amyloidosis is caused by deposition of transthyretin (TTR) fibrils in the heart, nerves and other organs. Patisiran is a siRNA that inhibits hepatic synthesis of TTR. This post-hoc analysis used single-beat pressure-volume (PV) techniques to delineate the effects of patisiran on cardiac function in the APOLLO trial. null null null Method null Noninvasive PV loops were constructed from core laboratory echocardiograms using LV volumes, Do...
Source
#1Veli K. Topkara (Columbia University)H-Index: 33
#2Kevin J. Clerkin (Columbia University)H-Index: 17
Last. Nir Uriel (Columbia University)H-Index: 51
view all 15 authors...
BACKGROUND One of the goals of the revised 6-tiered US adult heart allocation policy was to improve risk stratification of patients to lower exception status utilization for transplant listing. We sought to define the characteristics and outcomes of waitlisted patients using exception status and to examine region- and center-level differences in utilization of exception status in the new heart allocation system. METHODS This retrospective cohort analysis of the United Network for Organ Sharing d...
Source
#1Jan M. Griffin (Columbia University)H-Index: 4
#2Hannah Rosenblum (Columbia University)H-Index: 5
Last. Mathew S. Maurer (Columbia University)H-Index: 65
view all 3 authors...
Often considered a rare disease, cardiac amyloidosis is increasingly recognized by practicing clinicians. The increased rate of diagnosis is in part due the aging of the population and increasing incidence and prevalence of cardiac amyloidosis with advancing age, as well as the advent of noninvasive methods using nuclear scintigraphy to diagnose transthyretin cardiac amyloidosis due to either variant or wild type transthyretin without a biopsy. Perhaps the most important driver of the increased ...
1 CitationsSource
#2Pierre EliasH-Index: 5
Last. Mathew S. MaurerH-Index: 65
view all 10 authors...
Source
Source
Source
Source
Source